PureTech Founded Entity Seaport Therapeutics Announces Publication in Science Translational Medicine Featuring GlyphAllo™ (SPT-300) as the First Triglyceride-Mimetic Prodrug to Achieve Therapeutically Relevant Drug Levels in Humans
Sprout Social(US:SPT) Businesswire·2026-03-25 18:04BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Seaport Therapeutics Announces Publication in Science Translational Medicine Featuring GlyphAllo (SPT-300). ...